Idera Pharmaceuticals Announces Issuance of Patents for Novel Immune Modulatory Oligonucleotides Targeting Toll-Like Receptors and their Use
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel immune modulatory oligonucleotides (IMO), chemical modifications of IMOs, and methods of inducing an immune response through administering such compounds.
The issued patents include:- US 7,427,405, entitled "Immunostimulatory Oligonucleotide Multimers"
- US 7,407,944, entitled "Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends"
- US 7,405,285, entitled "Immunostimulatory Oligonucleotide Multimers"
- AU 2006203435, entitled "Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes"
"The claims of the recently issued patents cover novel compounds and methods of using these compounds, including our lead candidate for infectious disease, IMO-2125," said Steven Ritter, Ph.D., J.D., Vice President of Intellectual Property and Contracts. "We continue to expand the patent portfolio covering our synthetic, DNA-based Toll-like Receptor (TLR)-targeted compounds, which are created through our chemistry-based drug discovery approach to TLR-targeted therapy."
Presently, the Company holds over 250 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLR7, 8 and 9.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc., which involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on the Company's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborators will support the development and commercialization of products under their collaborations with the Company; whether the patents and patent applications owned or licensed by the Company will protect the Company's technology and prevent others from infringing it; whether the Company's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed on August 1, 2008, which important factors are incorporated herein by reference. The Company disclaims any intention or obligation to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.